A New "Non-Traditional" Antibacterial Drug Fluorothiazinone-Clinical Research in Patients with Complicated Urinary Tract Infections

• Published in: Antibiotics (Basel) 2024-05, Vol.13 (6), p.476
• Main Authors: Zigangirova, Nailya A, Lubenec, Nadezda L, Beloborodov, Vladimir B, Sheremet, Anna B, Nelyubina, Stanislava A, Bondareva, Nataliia E, Zakharov, Konstantin A, Luyksaar, Sergey I, Zolotov, Sergey A, Levchenko, Evgenia U, Luyksaar, Svetlana V, Koroleva, Ekaterina A, Fedina, Elena D, Simakova, Yana V, Pushkar, Dmitry Yu, Gintzburg, Alexander L
• Format: Article
• Language: English
• Subjects: Antibacterial agents; antibiotic-resistant bacteria; Antibiotics; Antiinfectives and antibacterials; Antimicrobial agents; Bacteria; Bacterial infections; Cefepime; Chlamydia; clinical trial; Clinical trials; complicated urinary tract infection; Diseases; Drug dosages; Drug resistance; Drug resistance in microorganisms; E coli; Effectiveness; Flagella; Fluorothiazinone; Health aspects; Medical research; Medicine, Experimental; non-traditional antibacterial agents; Pathogens; Placebos; Population; Relapse; Research facilities; Salmonella; small molecule T3SS and flagella inhibitor; Therapy; Urinary tract; Urinary tract diseases; Urinary tract infections; Urogenital system; Virulence
• ISSN: 2079-6382; 2079-6382
• DOI: 10.3390/antibiotics13060476

In order to combat resistance, it is necessary to develop antimicrobial agents that act differently from conventional antibiotics. Fluorothiazinone, 300 mg tablet (The Gamaleya National Research Center), is an original antibacterial drug based on a new small molecule T3SS and flagellum inhibitor. A total of 357 patients with complicated urinary tract infections (UTIs) were divided into two groups and given Fluorothiazinone 1200 mg/day or a placebo for 7 days to evaluate the efficacy and safety of the drug. Additionally, all patients were given Cefepime 2000 mg/day. Fluorothiazinone with Cefepime showed superiority over placebo/Cefepime based on the assessment of the proportion of patients with an overall outcome in the form of a cure after 21 days post-therapy (primary outcome), overall outcome in cure rates, clinical cure rates, and microbiological efficacy at the end of therapy and after 21 days post-therapy (secondary outcomes). In patients who received Fluorothiazinone, the rate of infection recurrences 53 and 83 days after the end of the therapy was lower by 18.9%, compared with patients who received placebo. Fluorothiazinone demonstrated a favorable safety profile with no serious unexpected adverse events reported. The results showed superiority of the therapy with Fluorothiazinone in combination with Cefepime compared with placebo/Cefepime in patients with cUTIs.